V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005207 | 10008268 | 1.7 | 74 | Palliative (P) | 2014-09-06 | 2014-09-07 | TEMOZOLOMIDE | 02 | N | 10338234 | PCV |
| 10005208 | 10008268 | 1.72 | 0 | Palliative (P) | null | 2018-03-04 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 2 | null | 10338234 | RUXOLITINIB |
| 10005209 | 10008268 | 1.62 | 75.45 | Disease modification (D) | 2018-02-19 | 2018-02-20 | Erlotinib | 2 | N | 10338234 | IRINOTECAN + MDG + PANITUMUMAB |
| 10005210 | 10008268 | 1.71 | 83 | Palliative (P) | 2017-06-30 | 2017-07-05 | Sorafenib | 02 | N | 10338234 | IRINOTECAN + MDG + PANITUMUMAB |
| 10005211 | 10008268 | 1.65 | 42 | Palliative (P) | 2017-01-11 | 2017-01-16 | IDELALISIB + RITUXIMAB | 02 | N | 10338234 | R-EPOCH |
| 10005212 | 10008268 | 1.67 | 100 | Palliative (P) | 2017-09-18 | 2017-09-19 | CARBOPLATIN + FLUOROURACIL | N | N | 10338234 | METHOTREXATE HIGH DOSE |
| 10005213 | 10008268 | null | null | Curative (C) | 2018-12-11 | 2019-01-15 | CAPECITABINE + MITOMYCIN + RT | null | N | 10338234 | NOT MATCHED |
| 10005214 | 10003253 | 1.87 | 60.9 | Curative (C) | 2016-10-26 | 2016-10-26 | ENRICH Trial | Y | Y | 10341799 | CHLVPP |
| 10005215 | 10003254 | 1.81 | 84.1 | null | null | 2016-12-12 | CISPLATIN + FLUOROURACIL | 2 | null | 10344577 | CAPECITABINE + CARBOPLATIN |
| 10005216 | 10003255 | 1.74 | 79.8 | Palliative (P) | 2016-05-01 | 2016-05-02 | Folfirinox | 02 | null | 10344932 | MITOMYCIN |
| 10005217 | 10003256 | null | 74 | Curative (C) | null | 2018-04-17 | MPT | N | N | 10346285 | CRIZOTINIB |
| 10005218 | 10003257 | 1.78 | 96.95 | null | 2015-10-22 | 2015-11-03 | Sorafenib | N | null | 10346867 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10005219 | 10003258 | null | 74.9 | Palliative (P) | 2017-07-05 | 2017-07-15 | Mitomycin Intravesical | N | N | 10347141 | SORAFENIB |
| 10005220 | 10003259 | null | null | Palliative (P) | 2017-05-13 | 2017-05-13 | Bortezomib + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 2 | N | 10348468 | DABRAFENIB |
| 10005221 | 10003259 | null | 84.2 | Palliative (P) | 2017-05-13 | 2017-05-14 | RCEOP | N | Y | 10348468 | IPILIMUMAB |
| 10005222 | 10003260 | 1.72 | 81.8 | Palliative (P) | 2017-05-07 | 2017-05-17 | CAPECITABINE + CISPLATIN + Trastuzumab | N | N | 10349419 | CAPECITABINE + CARBOPLATIN |
| 10005223 | 10006820 | 1.71 | null | Disease modification (D) | 2018-04-26 | 2018-05-18 | AC | 2 | N | 10350301 | NOT MATCHED |
| 10005224 | 10008269 | 1.71 | 87 | Curative (C) | 2019-01-24 | 2019-01-25 | CARBOPLATIN + PACLITAXEL + RT | N | N | 10351156 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005225 | 10008872 | 1.83 | 72.1 | Curative (C) | 2018-06-11 | 2018-06-23 | ECF | N | N | 10352406 | PREDNISOLONE + VINBLASTINE + RITUXIMAB |
| 10005226 | 10003261 | null | 96.7 | Palliative (P) | 2017-12-11 | 2017-12-21 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | Y | N | 10352625 | ECF |
| 10005227 | 10003262 | 1.82 | 91.6 | Adjuvant (A) | 2017-09-26 | 2017-10-03 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 10353954 | BORTEZOMIB + THALIDOMIDE |
| 10005228 | 10003262 | null | 84.8 | Palliative (P) | 2017-03-25 | 2017-03-26 | DA 3 + 10 | 02 | N | 10353954 | SUNITINIB |
| 10005229 | 10003262 | 1.7 | 58.15 | Palliative (P) | 2019-06-02 | 2019-06-08 | Cetuximab + Oxaliplatin + MdG Load | 02 | N | 10353954 | VINORELBINE |
| 10005230 | 10003262 | null | 67.6 | Adjuvant (A) | 2018-12-29 | 2019-01-07 | Cisplatin + Docetaxel +Fluorouracil | N | N | 10353954 | RIALTO TRIAL |
| 10005231 | 10003263 | 1.62 | 67 | Adjuvant (A) | 2018-02-27 | 2018-03-01 | Lenalidomide 25mg (Cycle 1 to 25) | 2 | N | 10358147 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005232 | 10003264 | null | 73.8 | Curative (C) | 2019-04-23 | 2019-04-30 | CVP | N | null | 10358351 | LIPOSOMAL DOXORUBICIN |
| 10005233 | 10003264 | 1.76 | 0 | Curative (C) | 2018-09-08 | 2018-09-08 | Bortezomib + MELPHALAN | Y | N | 10358351 | CHLORAMBUCIL + RITUXIMAB |
| 10005234 | 10008271 | null | 54.6 | Palliative (P) | 2018-08-31 | 2018-09-14 | Trastuzumab 21 day loading dose | 02 | N | 10360583 | CAPECITABINE + CARBOPLATIN |
| 10005235 | 10003265 | 1.67 | null | null | 2017-05-11 | 2017-05-27 | Cetuximab + Radiotherapy Load | 1 | N | 10361215 | IBRUTINIB |
| 10005236 | 10003266 | null | 40 | Curative (C) | 2017-03-08 | 2017-03-16 | AC | N | null | 10361242 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10005237 | 10003266 | 1.77 | null | Palliative (P) | 2018-11-12 | 2018-11-18 | RUXOLITINIB | N | N | 10361242 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005238 | 10003267 | 1.65 | 84.3 | Palliative (P) | 2018-01-09 | 2018-01-10 | AFATINIB | 02 | N | 10363525 | SORAFENIB |
| 10005239 | 10003268 | 1.77 | 69.05 | Palliative (P) | 2015-10-31 | 2015-11-24 | BLEOMYCIN | N | N | 10363878 | GEMCITABINE + NAB-PACLITAXEL |
| 10005240 | 10003269 | 1.8 | 70.5 | Curative (C) | 2018-10-14 | 2018-10-14 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10363941 | PAZOPANIB |
| 10005241 | 10003269 | 1.61 | 67 | Palliative (P) | 2017-05-22 | 2017-05-25 | Folfirinox | N | N | 10363941 | DABRAFENIB |
| 10005242 | 10003270 | 1.64 | 62 | Palliative (P) | 2017-05-23 | 2017-05-25 | MIC | 02 | N | 10364656 | CETUXIMAB + IRINOTECAN + MDG |
| 10005243 | 10003270 | 1.85 | 67.2 | Curative (C) | 2019-05-16 | 2019-05-30 | Cetuximab 14 day | 02 | N | 10364656 | SORAFENIB |
| 10005244 | 10003270 | 0 | 84.1 | Disease modification (D) | 2017-08-25 | 2017-08-26 | Cyclophosphamide + Docetaxel + Trastuzumab | N | N | 10364656 | CMF |
| 10005245 | 10003271 | 0 | 63.4 | Curative (C) | 2017-07-15 | 2017-07-19 | GEM-P | 02 | N | 10367277 | GEFITINIB |
| 10005246 | 10003272 | 1.79 | 75.3 | Palliative (P) | 2015-09-13 | 2015-09-13 | Doxorubicin + Olaratumab | 2 | null | 10367312 | CETUXIMAB + RT |
| 10005247 | 10003273 | 1.7 | null | Palliative (P) | 2017-08-30 | 2017-09-18 | null | 01 | N | 10369704 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10005248 | 10003273 | 1.83 | 63.2 | Curative (C) | 2018-03-31 | 2018-03-31 | Sunitinib | Y | N | 10369704 | IPILIMUMAB |
| 10005249 | 10003273 | 1.72 | 52.8 | Palliative (P) | 2018-08-04 | 2018-09-08 | Temozolomide 150mg/m2 | N | Y | 10369704 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005250 | 10003274 | 1.58 | 47 | Palliative (P) | 2017-11-18 | 2017-12-04 | Ofatumumab Monthly | N | N | 10370278 | PAZOPANIB |
| 10005251 | 10003275 | 1.64 | 69.5 | Palliative (P) | 2018-12-23 | 2018-12-26 | AML 18 TRIAL | 2 | N | 10371134 | CETUXIMAB + IRINOTECAN + MDG |
| 10005252 | 10003276 | null | null | Curative (C) | null | 2014-08-22 | FEC + DOCETAXEL + TRASTUZUMAB | 2 | N | 10371189 | FEC + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10005253 | 10003277 | 1.63 | 49.15 | Palliative (P) | 2017-09-07 | 2017-10-26 | Ipilimumab | 2 | N | 10371240 | TRASTUZUMAB |
| 10005254 | 10003278 | 1.51 | 66 | Palliative (P) | 2018-01-17 | 2018-01-27 | FLUOROURACIL + RT | 02 | N | 10371251 | ECARBOX |
| 10005255 | 10003278 | 1.78 | 73.6 | null | 2019-04-25 | 2019-05-16 | BLEOMYCIN | N | N | 10371251 | GEFITINIB |
| 10005256 | 10003278 | 1.65 | 0 | Palliative (P) | 2016-07-30 | 2016-08-04 | Sorafenib | N | N | 10371251 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |